<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Allergan &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/allergan/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Wed, 08 Dec 2021 10:52:48 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Allergan &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国A型肉毒毒素市场研究报告(中文版含税价人民币12,000元)</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguoaxingroududusushichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Fri, 07 May 2021 05:34:29 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[A型肉毒毒素]]></category>
		<category><![CDATA[BOTOX]]></category>
		<category><![CDATA[保妥适]]></category>
		<category><![CDATA[兰州生物]]></category>
		<category><![CDATA[肉毒杆菌]]></category>
		<category><![CDATA[艾尔健]]></category>
		<category><![CDATA[衡力]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=23943</guid>

					<description><![CDATA[CRI元哲的调研数据显示，A型肉毒毒素在中国市场2016-2019的销售额逐渐上升，从2016年的1.2亿元 上升到2019年的1.77亿元。2020年的年销售额约为1.64亿元 ，比2019年有所下降。其主要原因是COVID-19疫情影响到医疗美容市场。中国市场A型肉毒毒素销售额在2016-2020年的CAGR为8%。CRI元哲预测，在2021-2025年，A型肉毒毒素在中国的销售额会因为疫情的稳定而有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>自闭症和治疗市场报告 &#8211; 全球预测至2023年</title>
		<link>https://www.yuanzhezixun.com/zibizhenghezhiliaoshichangbaogao-quanqiuyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 11 Jan 2019 03:02:30 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[ASD]]></category>
		<category><![CDATA[Autism Disorder]]></category>
		<category><![CDATA[Autism treatment]]></category>
		<category><![CDATA[Bristol-Myers Squibb and Otsuka Holdings Co.]]></category>
		<category><![CDATA[Consern Pharma Private Limited]]></category>
		<category><![CDATA[Coronis Partners Ltd.]]></category>
		<category><![CDATA[Curemark LLC]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[Heptares Therapeutics Limited]]></category>
		<category><![CDATA[Intra-Cellular Therapies Inc.]]></category>
		<category><![CDATA[Johnson & Johnson Services]]></category>
		<category><![CDATA[Merck & CO Inc.]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Saniona AB]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Ltd]]></category>
		<category><![CDATA[普遍发育障碍]]></category>
		<category><![CDATA[自闭症]]></category>
		<category><![CDATA[自闭症谱系障碍]]></category>
		<category><![CDATA[阿斯伯格综合症]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16956</guid>

					<description><![CDATA[预计2017 - 2023年期间全球自闭症和治疗市场将以4.37％的复合年增长率增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
